Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

Dr. Dina Radenkovic, CEO of Gameto, discusses the key considerations for bringing iPSC-based fertility treatments to market from a regulatory and manufacturing perspective.

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

In a perfect world, every emerging biopharma company would have a clear short- and long-term vision leading up to launch.

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship ...

Traditional approaches to benchmarking brand performance have struggled to keep pace with industry dynamics. While individual ...

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

Auguston kicked off an animated session titled “The People Factor” by outlining all the ways in which the CEO role in ...